文献速递脑血管病神经重症与神经感染

西尼莫德减轻实验性脑出血周围水肿并改善生存

Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage.
PubMed 文献 · Stroke · 2019-09-27

该研究在胶原酶诱导的小鼠脑出血模型中,将123只小鼠随机分组,给予西尼莫德单次或多次治疗。结果显示西尼莫德显著减轻脑出血后72小时的出血周围水肿,多次治疗还改善神经功能缺损和10天生存率,并减少体重下降。

要点

  • 西尼莫德显著减轻小鼠脑出血后72小时的出血周围水肿。
  • 多次给药改善神经功能缺损评分和10天生存率。
  • 西尼莫德治疗组脑出血后体重下降更少。

核心结论

  • 西尼莫德减轻实验性脑出血后的出血周围水肿,提高生存率并减少感觉运动功能缺损。

研究设计与样本

  • 研究在123只小鼠中通过颅内注射0.075 U细菌胶原酶诱导脑出血。
  • 小鼠随机分为溶剂对照组、术后30分钟单次西尼莫德组和术后30分钟起连续3天每日3次西尼莫德组。

主要发现

  • 西尼莫德显著减轻脑出血后72小时磁共振成像测得的出血周围水肿(P=0.021)。
  • 西尼莫德显著减轻脑出血后72小时湿干法测得的出血周围水肿(P=0.04)。
  • 脑出血后24小时低剂量组出血周围水肿有减轻趋势(P=0.08)。
  • 多次西尼莫德治疗显著改善Garcia评分评估的神经功能缺损(P=0.03)。
  • 多次西尼莫德治疗组第10天生存率显著改善(P=0.037),且体重下降减少(P=0.036)。

临床怎么用

  • 提示西尼莫德等S1PR调节剂可能作为脑出血后减轻水肿和改善预后的候选药物,但需进一步人体研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Perihemorrhagic edema (PHE) is associated with poor outcome after intracerebral hemorrhage (ICH). Infiltration of immune cells is considered a major contributor of PHE. Recent studies suggest that immunomodulation via S1PR (sphingosine-1-phosphate receptor) modulators improve outcome in ICH. Siponimod, a selective modulator of sphingosine 1-phosphate receptors type 1 and type 5, demonstrated an excellent safety profile in a large study of patients with multiple sclerosis. Here, we investigated the impact of siponimod treatment on perihemorrhagic edema, neurological deficits, and survival in a mouse model of ICH. Methods- ICH was induced by intracranial injection of 0.075 U of bacterial collagenase in 123 mice. Mice were randomly assigned to different treatment groups: vehicle, siponimod given as a single dosage 30 minutes after the operation or given 3× for 3 consecutive days starting 30 minutes after operation. The primary outcome of our study was evolution of PHE measured by magnetic resonance-imaging on T2-maps 72 hours after ICH, secondary outcomes included evolution of PHE 24 hours after ICH, survival and neurological deficits, as well as effects on circulating blood cells and body weight. Results- Siponimod significantly reduced PHE measured by magnetic resonance imaging (P=0.021) as well as wet-dry method (P=0.04) 72 hours after ICH. Evaluation of PHE 24 hours after ICH showed a tendency toward attenuated brain edema in the low-dosage group (P=0.08). Multiple treatments with siponimod significantly improved neurological deficits measured by Garcia Score (P=0.03). Survival at day 10 was improved in mice treated with multiple dosages of siponimod (P=0.037). Mice treated with siponimod showed a reduced weight loss after ICH (P=0.036). Conclusions- Siponimod (BAF-312) attenuated PHE after ICH, increased survival, and reduced ICH-induced sensorimotor deficits in our experimental ICH-model. Findings encourage further investigation of inflammatory modulators as well as the translation of BAF-312 to a human study of ICH patients.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Bobinger T, Manaenko A, Burkardt P, et al. Siponimod (BAF-312) Attenuates Perihemorrhagic Edema And Improves Survival in Experimental Intracerebral Hemorrhage. Stroke. 2019. PMID: 31558140. doi:10.1161/STROKEAHA.119.027134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。